Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1951 2
1952 1
1953 1
1954 4
1955 1
1957 2
1965 1
1979 1
1985 5
1991 2
1994 1
1996 1
1998 2
2000 5
2001 3
2002 4
2003 9
2004 5
2005 11
2006 8
2007 3
2008 4
2009 7
2010 5
2011 5
2012 6
2013 5
2014 8
2015 9
2016 10
2017 14
2018 10
2019 9
2020 11
2021 19
2022 24
2023 21
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Gianni L, et al. Among authors: poirier b. Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6. Lancet Oncol. 2012. PMID: 22153890 Clinical Trial.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P. Gianni L, et al. Among authors: poirier b. Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11. Lancet Oncol. 2016. PMID: 27179402 Clinical Trial.
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.
Lambert G, Thedrez A, Croyal M, Ramin-Mangata S, Couret D, Diotel N, Nobécourt-Dupuy E, Krempf M, LeBail JC, Poirier B, Blankenstein J, Villard EF, Guillot E. Lambert G, et al. Among authors: poirier b. Clin Sci (Lond). 2017 Feb 1;131(4):261-268. doi: 10.1042/CS20160403. Clin Sci (Lond). 2017. PMID: 28108631 Review.
220 results